LO3A.F LONZA GROUP UNSP.ADR 1/10
- Market cap
- EUR 49.6B
- P/E
- 43.6x
- P/B
- 5.67x
- ROE
- -3.0%
- Dividend yield
- 0.76%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LO3A.F undervalued?
Graham numberThe Graham number of LONZA GROUP UNSP.ADR 1/10 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LONZA GROUP UNSP.ADR 1/10 fundamental analysis
No fundamental analysis for LONZA GROUP UNSP.ADR 1/10 yet.
LONZA GROUP UNSP.ADR 1/10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LONZA GROUP UNSP.ADR 1/10
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manuf…
Full company profileLONZA GROUP UNSP.ADR 1/10 financial statements
LONZA GROUP UNSP.ADR 1/10 annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 6.22B | 6.72B | 5.48B | 6.53B |
| Gross Profit | 2.44B | 1.95B | 1.79B | 2.31B |
| Operating Income | 1.36B | 873M | 879M | 1.36B |
| EBITDA | 2.11B | 1.50B | 1.50B | 2.08B |
| Net Income | 1.22B | 654M | 636M | -275M |
| EPS | 16 | 9.07 | 9.00 | -3.92 |
| Balance Sheet | ||||
| Total Assets | 17.4B | 16.8B | 19.7B | 19.0B |
| Total Liabilities | 6.69B | 7.34B | 10.3B | 9.78B |
| Shareholders' Equity | 10.6B | 9.45B | 9.33B | 9.13B |
| Cash & Short-term Investments | 1.34B | 1.47B | 1.11B | 719M |
| Cash Flow | ||||
| Operating Cash Flow | 1.02B | 1.39B | 1.27B | 1.16B |
| Capital Expenditure | 1.87B | 1.68B | 1.42B | 1.37B |
| Free Cash Flow | -852M | -294M | -143M | -217M |
| Ratios | ||||
| ROE | 11.5% | 6.9% | 6.8% | -3.0% |
| ROA | 7.0% | 3.9% | 3.2% | -1.4% |
| Net Profit Margin | 19.5% | 9.7% | 11.6% | -4.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LONZA GROUP UNSP.ADR 1/10 dividends
- Dividend yield
- 0.76%
- Forward dividend
- 0.55 EUR
- Payout ratio
- -
- Ex-dividend date
- May 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 282M | 4.02 | - |
| 2024 | CHF 288M | 4.08 | 45.3% |
| 2023 | CHF 263M | 3.65 | 40.2% |
| 2022 | CHF 228M | 3.07 | 18.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LONZA GROUP UNSP.ADR 1/10
- Insiders 0.00%
- Institutions 0.04%
- Public & others 99.96%
- Shares outstanding 698M
- Free float 697M
LONZA GROUP UNSP.ADR 1/10 company profile
- Company name
- LONZA GROUP UNSP.ADR 1/10
- Ticker
- LO3A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20,141
- Fiscal year end
- December
- Address
- Muenchensteinerstrasse 38, Basel, Switzerland, 4002
- Phone
- 41 61 316 81 11
- Website
- lonza.com
About LONZA GROUP UNSP.ADR 1/10
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
LONZA GROUP UNSP.ADR 1/10 management
10- Dr. Wolfgang Wienand Ph.D.Chief Executive Officer · born 1972
- Mr. Philippe DeeckeChief Financial Officer
- Mr. Jason BerndtExecutive VP & Head of Group Operations
- Mr. Daniel BuchtaHead of Investor Relations
- Mr. Andreas BohrerChief Legal & Corporate Affairs Officer
- Ms. Kim HarrelsonHead of Ethics & Compliance, ERM and Corporate Responsibility
- Mr. Hans TreesSenior VP & Global Head of Communications
- Ms. Jennifer ClancySenior Director of Global Marketing
- Ms. Nicoleta BaumgartnerChief Human Resources Officer · born 1971
- Dr. Matthias HofmannHead of Corporate Environment, Health, Safety & Global Sustainability